ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,541 to 3,560 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Dapivirine Vaginal Ring vs Placebo Vaginal Ring: Percentage of Participants With Pregnancy in Each Trial Arm Over the IP Use Period;43 of 1,306

20 of 652

0.2 points

-1.6 to 1.8

1,958NCT01539226

Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women

Dapivirine Vaginal Ring vs Placebo Vaginal Ring: All Adverse Events1,147 of 1,306

561 of 652

1.8 points

-1.3 to 5.1

1,958NCT01539226

Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women

Dapivirine Vaginal Ring vs Placebo Vaginal Ring: deaths from any cause2 of 1,306

3 of 652

-0.3 points

-1.2 to 0.2

1,958NCT01539226

Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women

Dapivirine Vaginal Ring vs Placebo Vaginal Ring: serious adverse events41 of 1,306

9 of 652

1.8 points

0.3 to 3.0

1,958NCT01539226

Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women

Integrated Protocol vs Current Protocol: Recovery Under the Integrated Program and the Standard Protocol910 of 1,100

682 of 857

3.1 points

-0.3 to 6.7

1,957NCT01785680

Moderate Acute Malnutrition (MAM) and Severe Acute Malnutrition (SAM) in Sierra Leone

Integrated Protocol vs Current Protocol: deaths from any cause42 of 1,100

35 of 857

-0.3 points

-2.1 to 1.5

1,957NCT01785680

Moderate Acute Malnutrition (MAM) and Severe Acute Malnutrition (SAM) in Sierra Leone

PF-07321332 300 mg + Ritonavir 100 mg vs Placebo: Number of Participants With Progression to a Worsening Status in 1 or More Self-reported COVID-19 Associated Symptoms Through Day 28-mITT1 Population735 of 970

737 of 986

1.0 points

-2.8 to 4.8

1,956NCT04960202

EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19

Obeldesivir vs Placebo: serious adverse events2 of 979

4 of 976

-0.2 points

-0.9 to 0.4

1,955NCT05715528

Study of Obeldesivir in Nonhospitalized Participants With COVID-19

Participants From Boceprevir Studies vs Participants From Narlaprevir Studies: Number of Participants That Discontinued the LTFU Due to SAEs19 of 1,907

0 of 47

1.0 points

-6.6 to 1.6

1,954NCT00689390

Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)

Participants From Boceprevir Studies vs Participants From Narlaprevir Studies: Number of Participants With Serious Adverse Events (SAEs) Reported During the LTFU136 of 1,907

2 of 47

2.9 points

-7.2 to 6.2

1,954NCT00689390

Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)

Participants From Boceprevir Studies vs Participants From Narlaprevir Studies: serious adverse events136 of 1,907

2 of 47

2.9 points

-7.2 to 6.2

1,954NCT00689390

Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)

Transdisciplinary Approach vs Multidisciplinary Approach: Depressive Symptoms24 of 545

95 of 1,408

-2.3 points

-4.4 to 0.0

1,953NCT03442322

Optimizing Care for Patients With Dementia

Dapivirine Vaginal Ring vs Placebo Vaginal Ring: HIV-1 Seroconversion According to Comprehensive HIV Testing Algorithm.82 of 1,302

61 of 650

-3.1 points

-5.8 to -0.6

1,952NCT01539226

Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women

Indomethacin Alone vs Indomethacin+Pancreatic Stent: deaths from any cause24 of 975

26 of 975

-0.2 points

-1.7 to 1.2

1,950NCT02476279

Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis

Indomethacin Alone vs Indomethacin+Pancreatic Stent: serious adverse events355 of 975

352 of 975

0.3 points

-4.0 to 4.6

1,950NCT02476279

Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis

TICAGRELOR vs CLOPIDOGREL: Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization21 of 964

16 of 985

0.6 points

-0.7 to 1.8

1,949NCT00391872

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

CHICA Control vs CHICA Asthma Module: Diagnosis Rate of Asthma54 of 937

87 of 1,010

-2.9 points

-5.2 to -0.5

1,947NCT01312805

Using Computers to Assist in the Treatment of Asthma in a Pediatric Setting

Intervention Group vs Delay Results Group: deaths from any cause2 of 966

2 of 978

0.0 points

-0.6 to 0.6

1,944NCT03170362

PRIME Care (PRecision Medicine In MEntal Health Care)

Intervention Group vs Delay Results Group: serious adverse events76 of 966

70 of 978

0.7 points

-1.6 to 3.1

1,944NCT03170362

PRIME Care (PRecision Medicine In MEntal Health Care)

IBD Cases With Mental Health Condition vs IBD Cases Without Mental Health Condition (Reference Group): Stream 2: Relative Risk of Bowel Symptoms (Quality of Life Indicator)148 of 295

473 of 1,648

21.5 points

15.4 to 27.5

1,943NCT05206734

Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=178"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=178

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01539226-14e85045",
        "title": "Dapivirine Vaginal Ring vs Placebo Vaginal Ring: Percentage of Participants With Pregnancy in Each Trial Arm Over the IP Use Period;",
        "summary": "43 of 1306 against 20 of 652; risk difference 0.2 points, 95% interval -1.6 to 1.8; NCT01539226, Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women",
        "record": "/library/comparisons/NCT01539226-14e85045",
        "nct_id": "NCT01539226",
        "kind": "outcome",
        "participants": 1958,
        "risk_difference": {
          "value": 0.0022501150893939233,
          "lower": -0.016019630753510244,
          "upper": 0.0177108411303464
        },
        "group_1": "43 of 1,306",
        "group_2": "20 of 652",
        "difference": "0.2 points",
        "interval": "-1.6 to 1.8",
        "trial_title": "Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women"
      },
      {
        "id": "NCT01539226-5a7057a2",
        "title": "Dapivirine Vaginal Ring vs Placebo Vaginal Ring: All Adverse Events",
        "summary": "1147 of 1306 against 561 of 652; risk difference 1.8 points, 95% interval -1.3 to 5.1; NCT01539226, Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women",
        "record": "/library/comparisons/NCT01539226-5a7057a2",
        "nct_id": "NCT01539226",
        "kind": "outcome",
        "participants": 1958,
        "risk_difference": {
          "value": 0.017824763479551642,
          "lower": -0.013084664518944873,
          "upper": 0.05101113351819796
        },
        "group_1": "1,147 of 1,306",
        "group_2": "561 of 652",
        "difference": "1.8 points",
        "interval": "-1.3 to 5.1",
        "trial_title": "Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=179",
  "request_id": "JBxWUtRbdPNIfTpB"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?